The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
Chimeric antigen receptor T (CAR-T) cell therapy has significantly transformed the management of cancer, specifically in patients suffering from leukemia and lymphoma. This treatment approach entails ...
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. This is an ASCO Meeting Abstract from ...
Scientists have devised new types of chimeric antigen-receptor (CAR) T cells -- a type of cancer immunotherapy -- that can be switched on to varying degrees of intensity and then switched off on ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results